Skip to content
The Policy VaultThe Policy Vault

Jakafi (ruxolitinib) — Highmark

Chronic graft-versus-host disease

Initial criteria

  • age ≥ 12 years
  • diagnosis of chronic graft-versus-host disease
  • therapeutic failure or intolerance to at least one systemic therapy

Reauthorization criteria

  • prescriber attests member is tolerating therapy and has experienced a therapeutic response defined as disease improvement OR delayed disease progression